ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

BACKGROUND: Many advanced hepatocellular carcinoma (HCC) patients are receiving sorafenib treatment. Sorafenib reportedly improves overall survival (OS) significantly in patients with HCC. Prediction of sorafenib response and prognosis in patients with HCC receiving sorafenib treatment are important...

Full description

Saved in:
Bibliographic Details
Published in:World J Gastrointest Oncol
Main Authors: Takaya, Hiroaki, Namisaki, Tadashi, Shimozato, Naotaka, Kaji, Kosuke, Kitade, Mitsuteru, Moriya, Kei, Sato, Shinya, Kawaratani, Hideto, Akahane, Takemi, Matsumoto, Masanori, Yoshiji, Hitoshi
Format: Artigo
Language:Inglês
Published: Baishideng Publishing Group Inc 2019
Subjects:
Observational Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522768/
https://ncbi.nlm.nih.gov/pubmed/31139312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v11.i5.424
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items